Raji/Human PD-L1 Stable Cell Line

IP Friendly
Cat. No. / Size
Price
Availability
Qty
SCRAJ-STT075-2Vials (1Vial X 2)
$5,355.00
In Stock - Delivery in 2-3 business days
SCRAJ-STT075
Sub-Total :
$ 0
0
Add to Cart
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
0
Add to Cart
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Advantages
  • Genetically modified cell lines best reflect MOA (Mechanism of Action)
  • Higher activity and larger assay window for robust and reproducible cell-based bioassay
  • Comprehensive application data to support assay development and validation
  • Full tracible record, stringent quality control and validated cell passage stability
  • Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  • Global commercial license assistance whenever regulatory filing is required
Description

The Raji/Human PD-L1 Stable Cell Line was engineered to express the full length human PD-L1 (Uniprot: Q9NZQ7-1), used to mimic cancer target cells. When co-cultured with human PD-1 Reporter Cell, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 interaction by either anti-PD-1 or anti-PD-L1 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.

Application

• Useful for cell-based PD-L1 binding assay

• Useful as PD-L1-expressing target cells in reporter gene assay

PD-L1 Assay Principles

Growth Properties

Suspension

Selection Marker

Puromycin (2 μg/mL)

Complete Growth Medium

RPMI-1640 + 10% FBS

Freeze Medium

Serum-free cell cryopreservation medium

Quantity

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

Storage

Frozen in liquid nitrogen.

Mycoplasma Testing

Negative

Sterility Testing

Negative

Instructions for Use

See data sheet for detailed culturing and assay protocol.

ACRO Scientific Leadership Award

Supporting the scientists driving cell & gene therapy forward

Apply Now